Key Performance
More- Earnings Score: 20
- Momentum Score: 35
- True Yield: N/A
- Financial Health Score: 8
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Azenta, Inc. (AZTA) faces an ongoing securities fraud investigation following disappointing Q2 2026 earnings results on May 5, 2026. The company missed consensus estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance, causing the stock to plummet 25.3% to $18.38 per share. A securities law firm is investigating potential federal securities law violations and urging affected shareholders to contact them.
05/22/2026, 1:21 PM • Benzinga
Levi & Korsinsky Announces Investigation of Securities Claims Against Azenta, Inc. (AZTA)
Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026, but disclosed a $149 million goodwill impairment tied to its Multiomics segment in May 2026, alongside a $160.8 million net loss and substantial guidance reduction. The company did not reference the impairment risk during its February reaffirmation, prompting an investigation into potential securities law violations.
05/21/2026, 9:00 AM • GlobeNewswire
Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.
05/19/2026, 6:23 PM • GlobeNewswire
Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% on May 6, 2026. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.
05/18/2026, 7:00 PM • GlobeNewswire
AZTA Investors Have Opportunity to Join Azenta, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm announced an investigation into Azenta, Inc. for potential securities law violations following the company's May 5, 2026 earnings announcement. Azenta missed analyst estimates on revenue and EPS due to execution shortfalls and weak demand, leading to a 25.3% stock price decline and a reduced full-year 2026 outlook.
05/18/2026, 2:43 PM • GlobeNewswire
Azenta, Inc. (NASDAQ: AZTA) recorded a $149 million goodwill impairment and slashed FY 2026 guidance on May 5, 2026, just weeks after reaffirming confidence in its growth trajectory on the Q1 earnings call. The impairment was tied to the Multiomics segment. Levi & Korsinsky is investigating whether the company made materially misleading statements to investors regarding risks to the Multiomics segment and factors underlying the goodwill impairment.
05/14/2026, 9:00 AM • GlobeNewswire
Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% from $24.61 to $18.38. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.
05/13/2026, 7:00 PM • GlobeNewswire
A securities fraud investigation has been announced against Azenta, Inc. after the company missed Q2 2026 earnings estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance. The stock fell 25.3% to $18.38 on May 6, 2026, prompting a law firm to seek investors who suffered losses.
05/13/2026, 1:32 PM • Benzinga
Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.
05/12/2026, 5:53 PM • GlobeNewswire
Azenta (AZTA) Stock Drops 13% After-Hours — What's Happening?
Azenta Inc (NASDAQ:AZTA) stock fell 13.65% in after-hours trading on Thursday following the filing of a Form 3 with the SEC. William E. Martin III, President of Multiomics at Azenta, submitted an initial statement of beneficial ownership indicating no securities are beneficially owned. The stock closed regular trading at $24.32 (up 3.68%) before declining to $21.00 after-hours.
04/17/2026, 1:46 AM • Benzinga
The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.
02/11/2026, 1:40 PM • GlobeNewswire
Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™
The biopreservation market is experiencing significant growth driven by healthcare expenditure, research investment, and regenerative medicine, with North America leading and Asia Pacific showing fastest potential expansion. Key challenges include storage logistics and sample transportation standards.
10/08/2025, 11:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.